Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1133

1.

Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.

Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, Guastaroba P, Grilli R, Maresta A.

Circulation. 2007 Jun 26;115(25):3181-8. Epub 2007 Jun 11.

2.

Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry.

Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, Sangiorgio P, Tarantino F, Geraci G, Castriota F, Tondi S, Saia F, Cooke RM, Guastaroba P, Grilli R, Marzocchi A, Maresta A.

Circulation. 2008 Feb 19;117(7):923-30. doi: 10.1161/CIRCULATIONAHA.107.730416. Epub 2008 Feb 4.

3.

Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry.

Campo G, Saia F, Percoco G, Manari A, Santarelli A, Vignali L, Varani E, Benassi A, Sangiorgio P, Tarantino F, Magnavacchi P, De Palma R, Guastaroba P, Marzocchi A.

Int J Cardiol. 2010 Apr 15;140(2):154-60. doi: 10.1016/j.ijcard.2008.11.021. Epub 2008 Dec 3.

PMID:
19056134
4.

Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).

Daemen J, Tanimoto S, García-García HM, Kukreja N, van de Sande M, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW.

Am J Cardiol. 2007 Apr 15;99(8):1027-32. Epub 2007 Mar 6.

PMID:
17437722
5.

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators..

Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26.

6.

Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents.

Kim YH, Park DW, Lee SW, Yun SC, Lee CW, Hong MK, Park SW, Seung KB, Gwon HC, Jeong MH, Jang Y, Kim HS, Seong IW, Park HS, Ahn T, Chae IH, Tahk SJ, Chung WS, Park SJ; Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization Investigators..

Circulation. 2009 Aug 4;120(5):400-7. doi: 10.1161/CIRCULATIONAHA.108.800805. Epub 2009 Jul 20.

7.

Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.

Migliorini A, Moschi G, Vergara R, Parodi G, Carrabba N, Antoniucci D.

Catheter Cardiovasc Interv. 2006 Mar;67(3):344-8.

PMID:
16489559
8.

Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.

Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJ; ZEST-AMI Investigators..

Am J Cardiol. 2009 Nov 15;104(10):1370-6. doi: 10.1016/j.amjcard.2009.06.059. Epub 2009 Sep 26.

PMID:
19892052
9.

Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).

Nienaber CA, Akin I, Schneider S, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Kuck KH; DES.DE Study Group..

Am J Cardiol. 2009 Nov 15;104(10):1362-9. doi: 10.1016/j.amjcard.2009.06.058. Epub 2009 Sep 26.

PMID:
19892051
10.

Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.

Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Alfonso F, Hernández-Antolín R, SanMartín M, Gómez-Hospital JA, Bañuelos C, Escaned J, Moreno R, Fernández C, Fernández-Avilés F, Macaya C; DIABETES Investigators..

Eur Heart J. 2007 Aug;28(16):1946-52. Epub 2007 Jun 11.

PMID:
17562666
11.

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators..

J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91. Epub 2006 Nov 2.

12.

Long-term efficacy and safety of drug-eluting stent implantation for patients with multiple coronary chronic total occlusions.

Zhang J, Han YL, Li Y, Wang SL, Jing QM, Wang XZ, Ma YY, Luan B, Wang G, Wang B.

Chin Med J (Engl). 2010 Apr 5;123(7):789-93.

PMID:
20497665
13.

Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.

Goswami NJ, Gaffigan M, Berrio G, Plessa AL, Pfeiffer AM, Markwell SJ, Mishkel GJ.

Catheter Cardiovasc Interv. 2010 Jan 1;75(1):93-100. doi: 10.1002/ccd.22194.

PMID:
19787803
14.

Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.

Jeong YH, Hong MK, Lee CW, Park DW, Kim YH, Kim JJ, Park SW, Park SJ.

Int J Cardiol. 2008 Mar 28;125(1):36-40. Epub 2007 May 22.

PMID:
17521753
15.

Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.

Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L.

Circulation. 2008 Nov 25;118(22):2277-85, 7p following 2285. doi: 10.1161/CIRCULATIONAHA.108.820159. Epub 2008 Nov 10.

16.

Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.

Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R; HORIZONS-AMI Trial Investigators..

N Engl J Med. 2009 May 7;360(19):1946-59. doi: 10.1056/NEJMoa0810116.

17.

Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.

Whan Lee C, Kim SH, Suh J, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ.

Catheter Cardiovasc Interv. 2008 Apr 1;71(5):594-8. doi: 10.1002/ccd.21399.

PMID:
18311841
18.

Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.

Jensen LO, Tilsted HH, Thayssen P, Kaltoft A, Maeng M, Lassen JF, Hansen KN, Madsen M, Ravkilde J, Johnsen SP, Sørensen HT, Thuesen L.

EuroIntervention. 2010 Apr;5(8):898-905. doi: 10.4244/.

PMID:
20542774
19.
20.

Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.

Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP; e-Cypher Investigators..

Circulation. 2006 Mar 21;113(11):1434-41. Epub 2006 Mar 13.

Supplemental Content

Support Center